Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer

被引：13

作者：

Heigener, David F. ^{[1
,2
,3
]}

Kerr, Keith M. ^{[4
]}

Laing, Gavin M. ^{[4
]}

Mok, Tony S. K. ^{[5
]}

Moiseyenko, Fedor V. ^{[6
,7
]}

Reck, Martin ^{[3
,8
,9
]}

机构：

[1] Helios Klinikum Schleswig, Dept Pulmonol, Schleswig, Germany

[2] Univ Kiel, Kiel, Germany

[3] Airway Res Ctr North German Ctr Lung Res DZL, Grosshansdorf, Germany

[4] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland

[5] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China

[6] Inst Oncol NN Petrov St Petersburg, Pesochny, Russia

[7] St Petersburg City Canc Ctr, St Petersburg, Russia

[8] LungenClin Grosshansdorf, Grosshansdorf, Germany

[9] Univ Lubeck, Lubeck, Germany

来源：

CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 16期

关键词：

PLATINUM-BASED CHEMOTHERAPY; DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; EGFR MUTATIONS; INTERNATIONAL ASSOCIATION; PHASE-III; AFATINIB; MULTICENTER; CRIZOTINIB; GEFITINIB;

D O I：

10.1158/1078-0432.CCR-18-1894

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic non-small-cell lung cancer is still a devastating disease; however, treatment options have diversified dramatically in the past two decades. From unselected platinum-based chemotherapy for all patients, several different treatment groups have evolved, that is, those with "druggable" targets, those with a promising immune signature, and those without any predicting factors outlined in this article. Challenge includes the intersections between these groups and the optimal treatment path. These issues will be addressed in this review.

引用

页码：4881 / 4887

页数：7

共 50 条

[21] Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?
Zugazagoitia, Jon
Ponce, Santiago
Paz-Ares, Luis
TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 95 - 97
[22] First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer
Lin, Jessica J.
Gainor, Justin F.
LANCET RESPIRATORY MEDICINE, 2023, 11 (04): : 302 - 304
[23] Topotecan active as first-line combination therapy for advanced non-small-cell lung cancer
不详
ONCOLOGY-NEW YORK, 2001, 15 (02): : 186 - +
[24] Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
Hayashi, H.
Okamoto, I.
Morita, S.
Taguri, M.
Nakagawa, K.
ANNALS OF ONCOLOGY, 2012, 23 (06) : 1537 - 1541
[25] Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
Xiang, Guiyuan
Gu, Lingna
Chen, Xuan
Wang, Fan
Chen, Bohua
Zhao, Jie
Lu, Yun
Chang, Feng
Zhu, Yumei
FRONTIERS IN PUBLIC HEALTH, 2021, 9
[26] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
Socinski, Mark A.
DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
[27] BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER IN CHINA
Zhang, Y.
Samuelsen, C. H.
Griebsch, I
Yao, Z.
VALUE IN HEALTH, 2018, 21 : S27 - S27
[28] Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer
Xin-Hua Xu
Jin Su
Xiang-Yang Fu
Feng Xue
Qiao Huang
Dao-Jun Li
Ming-Qian Lu
Cancer Chemotherapy and Pharmacology, 2011, 67 : 475 - 479
[29] Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer
Xu, Xin-Hua
Su, Jin
Fu, Xiang-Yang
Xue, Feng
Huang, Qiao
Li, Dao-Jun
Lu, Ming-Qian
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 475 - 479
[30] First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
Georgoulias, V
Androulakis, N
Dimopoulos, AM
Kourousis, C
Kakolyris, S
Papadakis, E
Apostolopoulou, F
Papadimitriou, C
Vossos, A
Agelidou, M
Heras, P
Tzannes, S
Vlachonicolis, J
Mavromanolakis, E
Hatzidaki, D
ANNALS OF ONCOLOGY, 1998, 9 (03) : 331 - 334

← 1 2 3 4 5 →